Chinese Biotech Company Vazyme To Show Full Line Of COVID-19 Testing Solutions At Medlab
Medlab has grown into a world renowned laboratory trade show and IVD trade show of international stature. Last year alone, the event attracted more than 23,000 medical laboratory, health and commerce professionals from more than 140 countries and regions around the world. This year’s exhibition will bring together more than 650 leading companies from over 40 countries and regions.
As one of the few innovative producers focused on research and development (R&D) in China which has capabilities in in-house upstream technology development and finished product manufacturing, Vazyme plans to exhibit several of its key offerings at the event, including COVID-19 Testing Solutions, alongside its testing instruments. exclusive in vitro diagnostics. This range of exposures is expected to play an important role in promoting health maintenance and preventing and controlling any further spread of COVID-19.
The highlights of Vazyme’s key products will include:
COVID-19[female[feminine detection kits:
- The complete nucleic acid detection solution;
- the COVID-19[female[feminine Antigen detection kit;
- The neutralizing antibody ELISA kit;
- The RBD protein IgG detection kit;
- The RBD Protein IgG ELISA kit;
- Reagents based on enzymatic material for COVID-19[female[feminine nucleic acid tests
- Other life science research reagents
With its strong R&D skills and vast technological expertise, Vazyme is committed to preventing and controlling the spread of COVID-19. After the onset of the disease, the company quickly completed the research and development of raw materials for nucleic acid diagnostic reagents and significantly improved the sensitivity and specificity of the detection kits while providing reagent manufacturers with materials. raw materials that can be used to produce more than 500 million diagnostic kits. In addition, the R&D team successfully developed an antibody detection kit based on the company’s key generic technology platform and displaying results within ten minutes. To date, Vazyme has exported over 30 million detection reagents worldwide. The company also introduced an antigen test kit that further improves the efficiency of detection before deploying neutralization and RBD. Protein IgG detection kits used to assess the efficacy of vaccines already available on the market and to help develop new, more effective vaccines.
Vazyme has greatly contributed to the prevention and control of the pandemic. In particular, the company has offered COVID-19 testing solutions to 19 countries and regions around the world after receiving approval from respective supervisory authorities, including, among others, the UK Medicines and Products Regulatory Agency. health (MHRA), that of Russia GOST, the Brazilian Health Regulatory Agency (ANVISA) and the Indonesian Food and Drug Authority.
To further expand its activities in global markets, Vazyme plans to further expand its portfolio of in vitro diagnostics by increasing its investments in the development of innovative solutions.
Information on the Vazyme stand
Date (Live exhibition): June 21-24, 2021
Location: Dubai World Trade Center, United Arab Emirates
Booth number: Z5.D40
Date (online exhibition): May 23 – July 22, 2021
About Nanjing Vazyme Biotech Co., Ltd
Founded in 2012, Vazyme is one of the few innovative R&D-focused biotechnology companies in China which has capabilities in in-house upstream technology development and manufacturing of finished products. With an ongoing commitment to innovation and on the basis of its proprietary key generic technology platform, the company has built a commercial network spanning biological research, in vitro diagnostics and biomedicine. Currently, the company has a portfolio of more than 200 types of genetically engineered recombinases, more than 1,000 types of high performance antigens, monoclonal antibodies and other key raw materials, in addition to more than 500 Finished products. In addition, Vazyme has developed eight series of POCT diagnostic reagents and associated control materials covering cardiovascular and cerebrovascular disease, inflammation, prepotency, gastric functions, autoimmunity, renal function, management of chronic illnesses as well as respiratory illnesses.
For more information, please visit the official Vazyme website at http://www.vazyme.com.